Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Average Recommendation of “Hold” from Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has earned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $40.00.

A number of equities analysts recently issued reports on SNSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday. They set a “buy” rating for the company. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company.

Insider Transactions at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder Millennium Management Llc purchased 15,321 shares of the firm’s stock in a transaction on Friday, March 27th. The stock was purchased at an average cost of $26.61 per share, for a total transaction of $407,691.81. Following the transaction, the insider owned 142,360 shares in the company, valued at $3,788,199.60. The trade was a 12.06% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have purchased 46,980 shares of company stock valued at $1,341,669 and have sold 23,067 shares valued at $704,439. Company insiders own 23.20% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNSE. Renaissance Technologies LLC increased its position in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares during the period. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at approximately $4,188,000. Bank of America Corp DE increased its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Vivo Capital LLC acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Price Performance

SNSE stock opened at $17.56 on Friday. The company has a 50 day simple moving average of $27.93 and a 200 day simple moving average of $18.17. The stock has a market cap of $23.53 million, a price-to-earnings ratio of -0.12 and a beta of -0.18. Sensei Biotherapeutics has a 1 year low of $5.25 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). On average, equities research analysts anticipate that Sensei Biotherapeutics will post -2.77 EPS for the current fiscal year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.